Frazier Financial Advisors LLC Decreases Stake in AstraZeneca PLC (NASDAQ:AZN)

Frazier Financial Advisors LLC cut its holdings in shares of AstraZeneca PLC (NASDAQ:AZN) by 18.5% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 762 shares of the company’s stock after selling 173 shares during the quarter. Frazier Financial Advisors LLC’s holdings in AstraZeneca were worth $50,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of the business. Cibc World Markets Corp lifted its stake in shares of AstraZeneca by 1.1% in the 4th quarter. Cibc World Markets Corp now owns 12,901 shares of the company’s stock valued at $845,000 after purchasing an additional 142 shares during the last quarter. Diversify Wealth Management LLC boosted its stake in AstraZeneca by 3.6% during the fourth quarter. Diversify Wealth Management LLC now owns 4,402 shares of the company’s stock worth $295,000 after buying an additional 153 shares during the period. Veery Capital LLC raised its stake in shares of AstraZeneca by 4.7% in the 4th quarter. Veery Capital LLC now owns 3,503 shares of the company’s stock valued at $230,000 after acquiring an additional 157 shares during the period. Rehmann Capital Advisory Group lifted its holdings in shares of AstraZeneca by 1.8% in the 3rd quarter. Rehmann Capital Advisory Group now owns 10,027 shares of the company’s stock worth $788,000 after acquiring an additional 175 shares during the last quarter. Finally, Dorsey & Whitney Trust CO LLC increased its holdings in AstraZeneca by 0.5% in the 4th quarter. Dorsey & Whitney Trust CO LLC now owns 35,300 shares of the company’s stock valued at $2,313,000 after purchasing an additional 189 shares during the last quarter. Hedge funds and other institutional investors own 20.35% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on the company. Morgan Stanley initiated coverage on AstraZeneca in a research note on Wednesday, February 12th. They issued an “overweight” rating for the company. UBS Group upgraded shares of AstraZeneca from a “neutral” rating to a “buy” rating in a research note on Thursday, February 13th. One research analyst has rated the stock with a hold rating, seven have assigned a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus target price of $89.75.

AstraZeneca Trading Up 0.2 %

Shares of NASDAQ:AZN opened at $72.84 on Friday. The company has a market cap of $225.89 billion, a PE ratio of 32.23, a P/E/G ratio of 1.42 and a beta of 0.41. The company’s 50 day moving average is $73.41 and its two-hundred day moving average is $71.79. AstraZeneca PLC has a 52 week low of $62.75 and a 52 week high of $87.68. The company has a current ratio of 0.93, a quick ratio of 0.74 and a debt-to-equity ratio of 0.65.

AstraZeneca (NASDAQ:AZN) last announced its quarterly earnings results on Thursday, February 6th. The company reported $1.05 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.10 by ($0.05). AstraZeneca had a return on equity of 32.23% and a net margin of 13.01%. Equities analysts predict that AstraZeneca PLC will post 4.51 earnings per share for the current fiscal year.

AstraZeneca Increases Dividend

The business also recently announced a semi-annual dividend, which was paid on Monday, March 24th. Stockholders of record on Friday, February 21st were issued a $1.03 dividend. This is a boost from AstraZeneca’s previous semi-annual dividend of $0.49. The ex-dividend date was Friday, February 21st. This represents a dividend yield of 2%. AstraZeneca’s dividend payout ratio is presently 91.15%.

AstraZeneca Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.